0
Lung Cancer: Lung Cancer III |

The Potential Effects of iTreg During Adoptive Immunotherapy With TCR-T Cell FREE TO VIEW

Huan Zhang, BA; Yi Li, PhD; Zhaoduan Liang, PhD
Author and Funding Information

State Key Laboratory of Respiratory Disease, Guangzhou, China


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;149(4_S):A318. doi:10.1016/j.chest.2016.02.331
Text Size: A A A
Published online

SESSION TITLE: Lung Cancer III

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: we will investigate the changes of iTreg function after the changing of T cell’ antigen avidity by NY-ESO-1 specific HAT, and study the effects of HAT engineered iTreg on the function of other immune cells.

METHODS: 1. Construct TCR lentiviral vectors with different affinity and pack lentivirus 2. Transduct and transfect different affinity-TCR genes into iTreg 3. Compare the difference of the ability between iTregs and HAT- iTreg (cytokine release, inhibition of antigen presentation and tumor cell killing) 4. Construct non-small cell lung cancer (NSCLC) animal model, and study the function of HAT- iTreg (tumor size, number of DC, NK, T cells in PBMC)

RESULTS: 1. iTreg can be efficiently induced with several combination of cytokine. 2. iTreg inhibit proliferation and tumor cell killing of CD8+ T cell 3. Transduction and transfection of different affinity-TCR genes into iTreg (HAT- iTreg)

CONCLUSIONS: iTreg has been successfully induced, and it has the ability to inhibit proliferation and tumor cell killing of CD8+ T cell. Meanwhile, different affinity-TCR genes could be transducted and transfected into iTreg, which provides us good opportunity to investigate the changes of iTreg function after the changing of T cell’ antigen avidity by NY-ESO-1 specific HAT, and study the effects of HAT engineered iTreg on the function of other immune cells.

CLINICAL IMPLICATIONS: These studies underscore the clinical utility of using optimised TCRs to endow adoptive immunotherapy for cancer as well as autoimmune disease and highlight the conditions in which this approach would have most therapeutic benefits.

DISCLOSURE: The following authors have nothing to disclose: Huan Zhang, Yi Li, Zhaoduan Liang

No Product/Research Disclosure Information


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543